lipodystrophy is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-18. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
As well as these common law standards, the Fair Work Act 2009 section 117 requires a bare minimum of 1 week's notice before 1 year, 2 weeks' notice for 2 years, 3 weeks' notice for over 3 years, and 4 weeks' notice for over 5 years, but also an extra week for employees over 45 years old who have worked more than 2 years. Modern awards can and often do have higher standards, and so do collective agreements. The dominant view is that courts may find greater notice is warranted where the facts speak in favour, because statute's purpose is to create a floor of rights, not a ceiling, that common law may improve upon, not undercut. An employer may give pay in lieu of notice under section 117(2) and terminate the contract if this has been accepted by the employee. The one situation where notice is not required is where a party commits a serious breach of contract. In these cases, an employee can quit on the spot and claim damages, or an employer can dismiss the employee. According to Bartlett v ANZ Banking Group Ltd a serious breach of the employment contract can include deliberate disobedience of a lawful and reasonable order, breaching the duty of fidelity (e.g. by taking secret commissions), or serious incompetence. In this case, an ANZ Bank employee won damages for wrongful dismissal on appeal, measured by 4 months notice that his contract required, since ANZ could not prove he had actually engaged in misconduct of sending confidential information to a journalist at the Australian Financial Review, and the employer had an obligation to act reasonably.
As suggested by the name, the biomass of the mycosymbiont is mostly exterior to the plant root. The fungal structure is composed primarily of three parts: 1) the intraradical hyphae making up the Hartig net; 2) the mantle that forms a sheath surrounding the root tip; and 3) the extraradical hyphae and related structures that spread throughout the soil.
October 8 – The US begins direct negotiations with the military junta while continuing sanctions against its leader, Min Aung Hlaing, for human rights violations, notably the Rohingya genocide. The Pentagon instructs the US Central Command to get ready in case direct military operations against Iran were to resume. U.S. and Israeli officials suggests that joint strikes against Iranian nuclear, energy, and infrastructure sites might take place prior to either the November US midterm elections or the late October Israeli general election, even though Trump had not made a final decision or established a timeline. Internal assessments and energy analysts cautions that renewed hostilities would fail to lower immediate gasoline prices and could instead cause a sharp spike in global oil prices, despite the administration's goal of a military breakthrough to eventually lower domestic fuel costs. Further sanctions are put by the US on Iran's shadow fleet.
Reprocessed uranium is also mainly 238U, with about as much uranium-235 as natural uranium, a comparable proportion of uranium-236, and much smaller amounts of other isotopes of uranium such as uranium-234, uranium-233, and uranium-232.
Sources: en.wikipedia.org
An angiogenesis inhibitor is a substance that inhibits the growth of new blood vessels (angiogenesis). Some angiogenesis inhibitors are endogenous and a normal part of the body's control and others are obtained exogenously through pharmaceutical drugs or diet. While angiogenesis is a critical part of wound healing and other favorable processes, certain types of angiogenesis are associated with the growth of malignant tumors. Thus angiogenesis inhibitors have been closely studied for possible cancer treatment. Angiogenesis inhibitors were once thought to have potential as a "silver bullet" treatment applicable to many types of cancer, but the limitations of anti-angiogenic therapy have been shown in practice. Currently, angiogenesis inhibitors are recognized for their improvement of cancer immunotherapy by overcoming endothelial cell anergy. Angiogenesis inhibitors are also used to effectively treat macular degeneration in the eye, and other diseases that involve a proliferation of blood vessels.
=== Eosin === Eosin is most often used as a counterstain to haematoxylin, imparting a pink or red colour to cytoplasmic material, cell membranes, and some extracellular structures. It also imparts a strong red colour to red blood cells. Eosin may also be used as a counterstain in some variants of Gram staining, and in many other protocols. There are actually two very closely related compounds commonly referred to as eosin. Most often used is eosin Y (also known as eosin Y ws or eosin yellowish); it has a very slightly yellowish cast. The other eosin compound is eosin B (eosin bluish or imperial red); it has a very faint bluish cast. The two dyes are interchangeable, and the use of one or the other is more a matter of preference and tradition.
Professor Sarbolouki was the editor of Molecules, an international journal devoted to synthetic organic chemistry and natural product chemistry. He was also chief editor of Iranian Journal of Chemistry & Chemical Engineering. Professor Sarbolouki died on September 1, 2009, and his body was buried in Tehran Cemeteries, at the block for national legends on September 2, 2009. The Vice President and Minister of Science delivered messages of condolence and his burial was attended by numerous Iranian academics, scholars and students.
Sioux Nation of Indians and was involved in the Black Hills Land Claim John Lowenthal (1947), lawyer and documentary filmmaker known for his defense of Alger Hiss Norman Dorsen (1950), professor at the New York University School of Law and former president of the American Civil Liberties Union Robert O. Harris (1951), labor lawyer and chairman of the National Mediation Board Norman Marcus (1953), New York City Planning Commission general counsel and zoning expert Richard H. Stern (1953), attorney and law professor David Braun (1954), music industry lawyer, former president of PolyGram Records Alvin Hellerstein (1954), US federal judge Isaac Shapiro (1954), head of international practice at Skadden, Arps, Slate, Meagher & Flom, former president of Japan Society Clarence Benjamin Jones (1956), attorney and advisor to Martin Luther King Jr. Jerome H. Kern (1957), founder of Wachtell, Lipton, Rosen & Katz, former CEO of Playboy and Colorado Symphony Bernard Nussbaum (1958), White House counsel under Bill Clinton Ezra G. Levin (1959), lawyer, co-chair of international law firm Kramer Levin Naftalis & Frankel David G. Trager (1959), judge on the United States District Court for the Eastern District of New York Robert Abrams (1960), Bronx borough president and New York state attorney general Frank Tuerkheimer (1960), Watergate prosecutor and former U.S. attorney for the Western District of Wisconsin José A. Cabranes (1961), judge of the U.S. Court of Appeals; first Puerto Rican to sit in a U.S. District Court; current trustee of Columbia University Michael B.
=== Lives Saved === A peer-reviewed research study published June, 2022 in the journal Nature Communications showed the effectiveness of fast/frequent testing using the novel low-cost and scalable saliva-based RT-qPCR assay for SARS-CoV-2 that bypasses RNA extraction called covidSHIELD reduced mortality in the community more than 4-fold relative to expected.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.